이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Neurocomputational Training to Improve Reward Responsiveness in Veterans With Anhedonia

2026년 11월 4일 업데이트: VA Office of Research and Development

Anhedonia, a reduction in motivation and in the ability to feel positive emotions, is widespread among Veterans across a range of psychiatric disorders. This impairment is associated with poorer psychosocial functioning and is resistant to first-line medication and psychotherapy treatments. However, interventions to improve anhedonia are sorely lacking. Reward learning supports motivation to seek rewards, and this mechanism can be enhanced by engaging in reward exploration. Our preliminary findings suggest that this approach can help improve reward responsiveness and positive mood among depressed and anxious individuals. Thus, the proposed research will test the preliminary efficacy of a computerized reward learning training in improving reward sensitivity and reducing anhedonia in Veterans. This new intervention could offer a novel remotely accessible treatment and help enhance the efficacy of existing evidence-based treatments for depression and other psychiatric conditions in Veterans.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

Anhedonia, which is characterized by reduced reward responsiveness and blunted positive affect, is widespread among Veterans across a range of psychiatric conditions, including depression and PTSD. Anhedonia manifests as reduced exploration of rewards in a range of domains, including social connectedness and workforce engagement, and is associated with poorer psychosocial functioning and reduced response to psychiatric treatment. Despite the prominence of anhedonia and these associated deficits, the treatment of impaired reward responsiveness and underlying mechanisms has received relatively little attention compared to punishment sensitivity and negative affect, particularly in Veteran populations. Moreover, pharmacological and behavioral treatments for depression have shown mixed results for anhedonia. Thus, there is a significant need for mechanistically informed interventions targeting anhedonia in Veterans.

Recent advances in computational psychiatry have shown that reward learning is a key top-down mechanism of reward exploration and foraging, which could be leveraged to develop cognitive training interventions for anhedonia. For instance, Bayesian reinforcement learning models have been particularly useful in disentangling various aspects of reward responsiveness, including reward prediction updating (learning) and reward maximization strategy. Within this framework, subjective anhedonia, has been robustly linked to lower learning-based reward maximization in the multi-arm bandit (MAB), a reward exploration task in which one must sample from various unknown options with the goal of maximizing rewards. Critically, a recent randomized clinical trial (RCT) from our group suggests that a MAB experimentally tuned to provide high variance of reward delivery can increase reward learning and associated reward maximization among clinically depressed and anxious individuals with anhedonia.

This proposal will capitalize on this approach to test the effectiveness of a novel neurocomputational cognitive training aimed at boosting reward sensitivity in Veterans with anhedonia. The specific aims are to : 1) examine the degree to which a reward learning training protocol (reward learning intensive training/ReLIT) changes the neurocomputations supporting reward sensitivity in Veterans with anhedonia (Aim 1); 2) test the effectiveness and optimal dosage of ReLIT in improving subjective markers of anhedonia, depression, and psychosocial functioning (Aim2), and 3) assess the degree to which the effects of ReLIT generalize to parallel measures of automatic affective processing (Aim 3).

In a 3-arm double-blind RCT, Veterans (N=120) with moderate to high anhedonia will be randomized to an 8-week protocol of: 1) sham training (non-active), 2) active ReLIT of moderate intensity, or 3) active ReLIT of high intensity. At baseline (pre-treatment), 8-weeks (post-treatment), and 16-weeks follow-up (8 weeks post-treatment), participants will complete an assessment MAB and 2 automatic affective processing tasks (while undergoing functional MRI for a subset of 75 participants). Bayesian computational modeling will be used to derive individual parameters of reward learning and reward maximization and to extract neural activity associated with dynamic updating of reward predictions. Clinical and affective measures will be collected at all 3 assessments and each treatment session.

This proposal aims to assess the preliminary efficacy of a novel intervention for improving healthy reward responsiveness and anhedonic pathology in Veterans, which is currently an underrepresented area of mental health treatment for Veterans. This mechanistically informed intervention could a) provide a scalable and cost-effective treatment for Veterans with anhedonia, relying on technology interface rather than clinician-guided administration, b) be used as an adjunctive training to boost the effectiveness of existing evidence-based treatments for Veterans, such as cognitive behavioral therapy.

연구 유형

중재적

등록 (추정된)

120

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • California
      • San Diego, California, 미국, 92161-0002
        • VA San Diego Healthcare System, San Diego, CA
        • 수석 연구원:
          • Katia Harle, MD
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • being a Veteran
  • having at least moderate levels anhedonia (Snaith-Hamilton Pleasure Scale score>=20)
  • having sufficient vision and reading skills to complete the study protocol
  • being willing to attend treatment and assessment sessions

Exclusion Criteria:

  • lifetime history of psychotic or bipolar I disorder
  • neurological/neurodevelopmental disorders or sensory deficits that may impact cognitive function to preclude completion of study procedure (including past loss of consciousness > 24 hours)
  • taking certain psychotropic medications that may impact goal-directed task performance (e.g., benzodiazepines, sedative hypnotics); pre-existing stable doses (same regimen for at least 30 days) of psychotropic medications, such as selective serotonin reuptake inhibitors (SSRIs), will be allowed
  • recent (past 3 months) or current severe alcohol or substance use disorder necessitating prioritization of substance use treatment
  • recent (past month) or current risk of suicidal/homicidal behavior necessitating urgent higher level of care
  • undergoing concurrent neuromodulation or cognitive-behavioral psychotherapy targeting depression, anhedonia, and/or PTSD

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: ReLIT - Moderate Intensity

This arm provides a moderate dose of the experimental treatment, i.e., ReLIT (Reward Learning Intensive Training).

This arm provides an active reward learning training.

실험적: ReLIT - High Intensity

This arm provides a high dose of the experimental treatment, i.e., ReLIT (Reward Learning Intensive Training).

This arm provides an active reward learning training.

가짜 비교기: ST (Sham Training)

This arm provides a non-training protocol matched for time and reward environment.

This arm provides an inactive reward learning training.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Snaith-Hamilton Pleasure Scale (SHAPS)
기간: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

Measure of anhedonia. Score range from 14 to 56, with higher scores indicating greater anhedonia severity.

Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Reward Maximization
기간: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

Computational parameter derived from participants' choices in a reinforcement learning task, capturing the degree to which individuals select the options they predict to be most rewarding.

Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Neural Activation to Reward Prediction Errors (RPEs)
기간: Baseline, Post-Treatment (8 weeks)

Average BOLD (Blood-Oxygenation-Level Dependent) % signal change (i.e., activation) associated with individuals' model-based RPE (difference between expected probability of reward and actual outcome received) during reinforcement learning.

Baseline, Post-Treatment (8 weeks)

2차 결과 측정

결과 측정
측정값 설명
기간
World Health Organization Quality of Life Scale (WHOQOL-BREF)
기간: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

Measures quality of life and life satisfaction. Includes 4 domain subscales: physical health (range 7-35), psychological health (range 6-30), social relationships (range 3-15), and environment (range 8-42). Higher scores indicate higher quality of life.

Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Patient Health Questionnaire-9 (PHQ-9)
기간: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

Measures depression severity. Scores range from 0 to 27. Higher scores indicate greater depression severity.

Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Approach Bias
기간: Baseline, Post-Treatment (8 weeks)

This metric assesses the degree to which individuals display an implicit approach bias towards positive/rewarding cues in an approach-avoidance task. It is computed as the mean response time difference between approach-positive and avoid-positive choices.

Baseline, Post-Treatment (8 weeks)
Automatic Positive Affective Processing
기간: Baseline, Post-Treatment (8 weeks)

A measure of implicit bias towards positive relative to negative cues in an affective go/no-go task, as measured but the standardized rate of hits (accurate identification of positive cues) minus standardized rate of false alarms (inaccurate identification of negative cues as positive).

Baseline, Post-Treatment (8 weeks)
Neural Activation Associated with Implicit Processing of Positive Cues
기간: Baseline, Post-Treatment (8 weeks)

Average BOLD (Blood-Oxygenation-Level Dependent) % signal change (i.e., activation) associated with the contrast of positive-Go vs negative-Go trials in an affective go/no-go task.

Baseline, Post-Treatment (8 weeks)
Neural Activation Associated with Approach Bias
기간: Baseline, Post-Treatment (8 weeks)

Average BOLD (Blood-Oxygenation-Level Dependent) % signal change (i.e., activation) associated with the contrast of (positive-approach vs positive-avoid) minus (neutral-approach vs neutral-avoid) in an approach-avoidance task.

Baseline, Post-Treatment (8 weeks)

기타 결과 측정

결과 측정
측정값 설명
기간
Inventory of Psychosocial Functioning (IPF)
기간: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

The scale measures the degree of impairment in ability to interact effectively with others, fulfill social roles (e.g., work), and meet personal and societal expectations. It is comprised of 7 subscales. Each item ranges from 0 to 6. Higher scores indicate greater degree of impairment in psychosocial functioning.

Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Mood and Anxiety Symptoms Questionnaire (MASQ-D30)
기간: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

Measure of anhedonic depression, anxiety, and stress symptoms. The scale has three subscales (general distress, anhedonic depression, and anxious arousal) , with each score ranging from 10 to 50. Higher scores indicate greater severity of symptoms.

Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Reaction to Treatment Questionnaire
기간: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

Measure of treatment satisfaction and credibility of treatment rationale. Total scores range from 3 to 27, with higher scores indicating greater satisfaction and credibility in the treatment.

Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Liebowitz Social Anxiety Scale (LSAS)
기간: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

Assesses the impact of social anxiety on multiple aspects of life. Scores range from 0 to 144, with higher scores indicating greater social anxiety.

Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Positive and Negative Affect Schedule (PANAS)
기간: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

Assess positive and negative mood using a 5-point frequency scale (1-5). Each subscale (positive or negative affect) range from 10 to 50.

Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Social Connectedness Scale - Revised (SCS-R)
기간: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

Measures the degree to which individuals feel connected to others in their social environment. Scores range from 20 to 120, where higher scores indicate a stronger, healthier sense of social connectedness.

Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Foraging Task
기간: Baseline, Post-Treatment (8 weeks)

Measures performance and computational parameters associated with approach and avoidance biases in a dynamic foraging task.

Baseline, Post-Treatment (8 weeks)
Beck Anxiety Inventory (BAI)
기간: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

This scale measures anxiety severity. Scores range from 0 to 63, with higher scores indicating greater anxiety severity.

Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
PTSD Checklist-5 (PCL-5)
기간: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

Measures post-traumatic stress disorder (PTSD) severity. Scores range from 0 to 80, with higher scores indicating greater PTSD severity.

Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Behavioral Activation for Depression Scale (BADS)
기간: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

This scale measures changes in activation and avoidance behaviors. Items are measured on a 7-point Likert scale (0-6). Scores range from 0 to 150, with higher scores indicating greater behavioral activation.

Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Quick Structured Clinical Interview for DSM-5 (QuickSCID-5)
기간: Baseline , Post-Treatment (8-weeks)

Measures psychological diagnoses, which will be used to assess primary diagnostic category (i.e., depressive vs traumatic stress/anxiety disorder).

Baseline , Post-Treatment (8-weeks)
Neural Activation to Anticipated Reward
기간: Baseline, Post-Treatment (8 weeks)

Average BOLD (Blood-Oxygenation-Level Dependent) % signal change (i.e., activation) associated with individuals' model-based reward prediction/anticipation for chosen options during reinforcement learning.

Baseline, Post-Treatment (8 weeks)
Learning Rate
기간: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

Computational parameter derived from participants' choices in a reinforcement learning task, capturing the degree to which individuals are updating their dynamic reward predictions.

Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Specific Loss of Interest and Pleasure Scale (SLIPS)
기간: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

This is a measure of social anhedonia, i.e., hypo-responsiveness to social rewards, such as positive human interactions. Scores range from 0 to 69. Higher scores indicate greater severity of social anhedonia.

Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Katia Harle, MD, VA San Diego Healthcare System, San Diego, CA

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2027년 7월 1일

기본 완료 (추정된)

2030년 12월 31일

연구 완료 (추정된)

2031년 3월 31일

연구 등록 날짜

최초 제출

2026년 11월 4일

QC 기준을 충족하는 최초 제출

2026년 11월 4일

처음 게시됨 (실제)

2026년 11월 10일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 10일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 4일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • MHBC-006-26S

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

One or more data sets without personal identifiers will be generated during the data analysis phase of this study. The data sets will include all data underlying any publications generated by this study as well as statistical code, and therefore these will be sufficient to reproduce or verify any published findings.

Any HIPAA identifiers, or combinations of variables that could be used for re-identification, will be excluded, as will any proprietary information. The plan does not include any access to individually identifiable or proprietary data. Therefore, this plan will ensure the protection of personal privacy, the confidentiality of individually identifiable private information, and the security of proprietary data and information.

IPD 공유 기간

IPD and supporting information will become available upon completion of the study and publication of the the results.

IPD 공유 액세스 기준

Final de-identified datasets in machine-readable format will be submitted to and accessed from PubMed Central (and similar sites); care will be taken to ensure that individuals cannot be re-identified using other publicly available information.

IPD 공유 지원 정보 유형

  • ANALYTIC_CODE

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .